John Lunger
Corporate Officer/Principal bij ADAPTIMMUNE THERAPEUTICS PLC
Vermogen: 138 612 $ op 31-03-2024
Profiel
John Lunger is currently the Chief Patient Supply Officer at Adaptimmune Therapeutics Plc.
He previously worked as an Independent Director at Genocea Biosciences, Inc. and as the Head-Supply Chain & Commercial Product Supply at Merrimack Pharmaceuticals, Inc. Mr. Lunger completed his undergraduate degree at the United States Naval Academy and holds an MBA from The University of Chicago Booth School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 17-01-2024 | 479 027 ( 0.08% ) | 126 171 $ | 31-03-2024 | |
| 12-01-2024 | 7 874 ( 0.00% ) | 12 441 $ | 31-03-2024 |
Actieve functies van John Lunger
| Bedrijven | Functie | Begin |
|---|---|---|
| ADAPTIMMUNE THERAPEUTICS PLC | Corporate Officer/Principal | 01-03-2017 |
Eerdere bekende functies van John Lunger
| Bedrijven | Functie | Einde |
|---|---|---|
| MERRIMACK PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
| GENOCEA BIOSCIENCES, INC. | Director/Board Member | - |
Opleiding van John Lunger
| United States Naval Academy | Undergraduate Degree |
| The University of Chicago Booth School of Business | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 3 |
|---|---|
| GENOCEA BIOSCIENCES, INC. | Health Technology |
| MERRIMACK PHARMACEUTICALS, INC. | Health Technology |
| ADAPTIMMUNE THERAPEUTICS PLC | Health Technology |
